|Titre :||Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C|
|Titre original:||(L'usage quotidien de cannabis comme facteur de risque de progression vers une fibrose en cas d'hépatite C chronique)|
|Auteurs :||C. HÉZODE ; F. ROUDOT-THORAVAL ; S. NGUYEN ; P. GRENARD ; B. JULIEN ; E. S. ZAFRANI ; J. M. PAWLOTSKY ; D. DHUMEAUX ; S. LOTERSZTAJN ; A. MALLAT|
|Type de document :||Périodique|
|Année de publication :||2006|
|Format :||63-71 / graph. ; tabl.|
|Note générale :||
Hepatology, 2006, 42, (1), 63-71, graph. ; tabl.
|Discipline :||PAT (Pathologie organique / Organic pathology)|
Thésaurus TOXIBASECANNABIS ; FIBROSE ; HEPATITE ; USAGE REGULIER ; FACTEUR DE RISQUE ; FOIE ; ALCOOL
|Résumé :||Cannabinoids present in Cannabis sativa (marijuana) exert biological effects via cannabinoid receptors CB1 and CB2. We recently demonstrated that CB1 and CB2 receptors regulate progression of experimental liver fibrosis. We therefore investigated the impact of cannabis smoking on fibrosis progression rate in patients with chronic hepatitis C (CHC). Two hundred seventy consecutive untreated patients with CHC of known duration undergoing liver biopsy were studied. Demographic, epidemiological, metabolic, and virological data were recorded, and detailed histories of cannabis, alcohol, and tobacco use over the span of hepatitis C virus infection were obtained. Fibrosis stage, steatosis, and activity grades were scored according to Metavir system. Patients were categorized as noncannabis users (52.2%), occasional users (14.8%), or daily users (33.0%), and the relationship between cannabis use and fibrosis progression rate (FPR) or fibrosis stage was assessed. On multivariate analysis, six factors were independently related to a FPR greater than 0.074 (median value of the cohort): daily cannabis use (OR = 3.4 [1.5-7.4]), Metavir activity grade A2 or higher (OR = 5.4 [2.9-10.3]), age at contamination of more than 40 years (OR = 10.5 [3.0-37.1]), genotype 3 (OR = 3.4 [1.5-7.7]), excessive alcohol intake (OR = 2.2 [1.1-4.5]), and steatosis (OR = 2.0 [1.0-4.1]). Daily cannabis use was also an independent predictor of a rapid FPR (>0.15) (OR = 3.6 [1.5-7.5]). Finally, severe fibrosis (>=F3) was also predicted by daily cannabis use (OR = 2.5 [1.1-5.6]; P = .034), independently of Metavir activity grade, excessive alcohol intake, age at liver biopsy, steatosis, and tobacco smoking. In conclusion, daily cannabis smoking is significantly associated with fibrosis progression during CHC. Patients with ongoing CHC should be advised to refrain from regular cannabis use.|
|Domaine :||Plusieurs produits / Several products|
|Refs biblio. :||40|
Service d'Hépatologie et de Gastroentérologie, Hôp. Henri Mondor, A51 av. du Maréchal de Lattre de Tassigny, 94010 Créteil cedex.
|Numéro Toxibase :||1301556|
|Centre Emetteur :||13 OFDT|